Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06550011 · ClinicalTrials.gov registry record · Phase 1
Clinical Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of Intravitreal (IVT) Injection of ABI-110 (AAV2.N54-VEGF Trap) in Subjects With Neovascular (Wet) Age-Related Macular Degeneration (wAMD), Including Symptomatic Macular Polypoidal Choroidal Vasculopathy (PCV)
A Phase 1 study of Neovascular (Wet) AMD, sponsored by Avirmax Biopharma.
- Active
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
- 4
- Study locations
NCT06550011: Active Phase 1 study of Neovascular (Wet) AMD, sponsored by Avirmax Biopharma.
NCT06550011 is a Phase 1 study of Neovascular (Wet) AMD that is active but no longer recruiting, run by Avirmax Biopharma. The registered enrollment target is 18 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (70% lower). The trial reports 4 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06550011, a Phase 1 study of Neovascular (Wet) AMD, is active but no longer recruiting, sponsored by Avirmax Biopharma.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
- 4
- Study locations
Study Summary
This will be a clinical study to assess initial safety and tolerability of IVT ABI-110 in patients diagnosed with wet macular degeneration (wAMD), including symptomatic macular PCV.
Primary Outcome
Incidence of Treatment-Emergent Adverse Events \[Safety and Tolerability\]
Conditions Studied
Interventions
- DRUG ABI-110 Low Dose
- DRUG ABI-110 Medium Dose
- DRUG ABI-110 High Dose
Study Locations (4)
California
- California Retina Consultants - Bakersfield
- Bay Area Retina Associates - Walnut Creek
Texas
- Retina Consultants of Texas - San Antonio - San Antonio
- Retina Consultants of Texas - The Woodlands
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2024-08-07 |
| Est. Completion | 2031-01-16 |
| Phase | Phase 1 |
What the registry record for NCT06550011 still lists
NCT06550011 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 18 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (70% lower).
The record links to 1 condition, with Neovascular (Wet) AMD appearing as the primary indexed condition, and to 3 interventions - of which ABI-110 Low Dose is the first listed.
NCT06550011 reports a single indexed study location in California, Texas.
Frequently Asked Questions
What is clinical trial NCT06550011 about?
NCT06550011 is a clinical study titled "Clinical Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of Intravitreal (IVT) Injection of ABI-110 (AAV2.N54-VEGF Trap) in Subjects With Neovascular (Wet) Age-Related Macular Degeneration (wAMD), Including Symptomatic Macular Polypoidal Choroidal Vasculopathy (PCV)". This will be a clinical study to assess initial safety and tolerability of IVT ABI-110 in patients diagnosed with wet macular degeneration (wAMD), including symptomatic macular PCV.
What is the current status of trial NCT06550011?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2024-08-07. Estimated completion is 2031-01-16.
What conditions does trial NCT06550011 study?
This clinical trial studies the following conditions: Neovascular (Wet) AMD.
What interventions are being tested in trial NCT06550011?
The interventions under investigation include: ABI-110 Low Dose (DRUG), ABI-110 Medium Dose (DRUG), ABI-110 High Dose (DRUG).
Who is sponsoring clinical trial NCT06550011?
This trial is sponsored by Avirmax Biopharma, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06550011 being conducted?
This trial has 4 study locations across California, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06550011's enrollment target sits among peer trials
18 1720th of 2000 higher than 216 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01245179 · 18 participants · Phase 1
Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease
- NCT01999361 · 18 participants · NA
Prevention of de Novo Allosensitization in Islet Transplant Recipients Following Complete Graft Loss
- NCT02359825 · 18 participants · Phase 1
Nerve Repair Using Hydrophilic Polymers to Promote Immediate Fusion of Severed Axons and Swift Return of Function
- NCT02870244 · 18 participants · Phase 1
Adoptive T Cell Immunotherapy for Advanced Melanoma Using Engineered Lymphocytes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI